Met One Instruments Inc.

AVANIR Pharmaceuticals Presents Detailed Zenvia Confirmatory Phase III Results in Late-Breaker Session at American Neurological Association Meeting.
Biotech Week; 10/28/2009; 1837 words; ...Pharmaceuticals, Inc. (NASDAQ: AVNR...mg and 20/10 mg met the primary efficacy...20/10 mg groups met the primary efficacy...Pharmaceuticals, Inc.). A 30% decrease...episodes of PBA and may one day help improve the...LS is a validated instrument measuring the frequency...

Avanir Pharmaceuticals Discloses Zenvia Confirmatory Phase III Results.
Health & Beauty Close-Up; 10/17/2009; 1612 words; ...Avanir Pharmaceuticals, Inc. has announced detailed...10 mg and 20/10 mg met the primary efficacy endpoint...and 20/10 mg groups met the primary efficacy endpoint...episodes of PBA and may one day help improve the lives...CNS-LS is a validated instrument measuring the frequency...

Davao dad questions legitimacy of Apo Credit Coop.
Philippines News Agency; 10/14/2009; 1197 words; ...Asia Care Plans, Inc. (Pacpi) which...Dayanghirang said. One of those who claimed...Delinea is just one of the almost 15...Traditional Securities and Instruments Department issued...busy hopping from one place to another...last August 22, and met with many Pacpi plan...

New Birth-to-Six Assessment System to Focus on Key Predictors of School Success
U.S. Newswire; 10/13/2009; 882 words; ...children. "This is one of the most important...Teaching Strategies, Inc. "Assessment information...whether a child has met a particular state standard...be used to revise the instrument as necessary and provide...Teaching Strategies, Inc.

AVANIR Pharmaceuticals Presents Zenvia Phase III Results in Multiple Sclerosis Patient Population at Controversies in Neurology Congress.
Business Wire; 10/9/2009; 2370 words; ...AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today...subset, Zenvia 30/10 mg met the primary efficacy endpoint...Zenvia 30/10 mg dose met the primary endpoint in...CNS-LS is a validated instrument measuring the frequency...Zenvia 20/10 mg group. One MS patient in the Zenvia...